TP53 and breast cancer: By not stimulating or provoking the cell lines, except doxorubicin treatment to measure apoptotic resistance, our assay results likely captured the functional impact of the founding driver mutations in TP53 close to physiological conditions at the early stage of breast cancer development in vivo.